Almirall S.A (E2Z F) stock market data APIs
€12.2472
0(0%)
as of November 17, 2025
Try our APIs with
free plan!
Almirall S.A Financial Data Overview
Price chart is built with
Anychart
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Prev. Close
12.2472
Open
12.2472
High
12.2472
Low
12.2472
52 wk Range
7.9466-12.64
Market Cap
2 648 M
P/E Ratio
61.1
Shares Outstanding
215 M
Revenue
1 085 M
Dividends (Yield)
0
Beta
0.167
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Almirall S.A data using free add-ons & libraries
Get Almirall S.A Fundamental Data
Almirall S.A Fundamental data includes:
- Net Revenue: 1 085 M
- EBITDA: 211 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: 0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Almirall S.A News
New
Exploring Almirall’s (BME:ALM) Valuation Following Recent Share Price Strength
Almirall (BME:ALM) shares edged higher today, gaining just under 2%. This move has caught the attention of investors, who are keen to understand what might be driving sentiment for the Spanish pharmac...
Almirall SA (FRA:E2Z) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
This article first appeared on GuruFocus. Net Sales Growth: Nearly 13% year-on-year increase in the first nine months of 2025. Gross Margin: Moderated to 64.9% of sales, reflecting ongoing pressure r...
Almirall’s 2025 9M Results
Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress ...
United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall
Company Logo The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
